Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanadelumab for COVID-19
NCT04422509Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2020
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of lanadelumab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Oxygen at 2 weeks. Started Oct 2020; status: completed.
02
Drugs
lanadelumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04422509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04422509.